Sterile filterability. High-MW HA (>1,500 kDa) solutions at 0.5-2.0% w/v are often too viscous for 0.22 μm sterile filtration, requiring alternative and more costly sterilization approaches such as steam sterilization (which degrades HA), gamma irradiation (which cleaves polymer chains unpredictably), or aseptic compounding from sterile raw materials (logistically difficult). Mid-MW (600-1,300 kDa) HA can be sterile-filtered at clinically relevant concentrations, enabling simpler, faster, and more cost-effective aseptic manufacturing. Additionally, the lower solution viscosity improves syringe filling line throughput and reduces injection force — a meaningful patient compliance advantage in multi-injection regimens. If your target product profile includes single-injection viscosupplementation with maximum residence time, high-MW may be preferred; if sterile filterability and practical processability are priorities, mid-MW is the optimal choice.

Yes. Clinical studies show mid-MW HA injections provide significant pain reduction and functional improvement in knee osteoarthritis, with the added benefit of potentially better joint tissue penetration due to smaller chain size. Some evidence suggests mid-MW HA may provide faster initial symptomatic relief while high-MW HA may provide longer duration. Both MW ranges have demonstrated efficacy; the choice often comes down to manufacturing considerations (mid-MW is filterable, high-MW is not), injection protocol (single vs multi-injection), and target patient population.

<0.05 EU/mg — 10× stricter than ophthalmic grade (<0.5 EU/mg) and 100× stricter than cosmetic grade (<5 EU/mg). This stringent endotoxin control is essential for parenteral safety since injectable products directly enter joints, dermal tissue, or the eye interior — bypassing all natural barrier systems. Even trace levels of bacterial endotoxins can trigger pyrogenic responses, inflammation, and sterile abscess formation when injected. Every batch is tested by LAL assay per EP/USP <85>.

It can serve as a base HA for crosslinked dermal filler production, but most filler manufacturers prefer higher MW HA (>1,500 kDa) for greater crosslinking efficiency, gel firmness, and lift capacity. This mid-MW injection grade is better suited for viscosupplementation, OVDs, post-surgical adhesion barriers, and injectable drug delivery applications where filterability, syringeability, and tissue compatibility are more important than maximum gel firmness. For softer, more spreadable filler gels (fine-line fillers, skin boosters, mesotherapy), mid-MW HA can be an appropriate starting material.

COA with EP monograph data, bacterial endotoxin certificate (<0.05 EU/mg), MSDS, TSE/BSE statement, DMF Type IV filing support with Letter of Authorization, stability data (36-month real-time + 6-month accelerated), full lot traceability, and GMP compliance statement. ISO 9001:2015, c-GMP (ICH Q7, 21 CFR 210/211), FDA registered, HALAL, KOSHER. Audit access to manufacturing facility available for qualified pharmaceutical partners.